British scientists are claiming that a potential cure for cancer could be ready by 2018, reported express.co.uk. They are already in the process of developing an immune therapy based on blood cells of patients who have magically recovered from cancer. They believe that this breakthrough could save millions of lives suffering from this disease. The scientists also got a signal for better treatment for cancer from the early tests conducted in the laboratory.
According to the IANS reports, the cancer research bodies in the UK described the breakthrough as “very promising.”
The scientists claimed that they have found a way to extract the cancer-killing immune cells from donor blood and then multiply them by the million.
The main therapy involves neutrophil cells, it forms the first line of defence against foreign invaders in the body. The cancer cells get killed by Neutrophils. It destroys the cancer cells with chemicals or antibodies or
indirectly by recruiting other immune system cells.
Chief Executive of LIfT Biosciences, a leading biotech company, Alex Blyth said, “We’re not talking about simply managing cancer. We’re looking at a curative therapy that you would receive once a week over five to six weeks.” The leading biotech company now preparing for early trials on patients.
Blyth also added,”Based on our laboratory and mouse model experiments, we would hope to see patients experiencing complete remission. Our ultimate aim is to create the world’s first cell bank of immensely powerful cancer-killing neutrophils.”
He also explained that the major advantage of neutrophil treatment is that a donor’s cells can be given to anyone without fear of serious rejection. Only for five days they live in the body and disappear before the recipient’s immune system has got into gear.
As per as the express.co.uk, Anna Perman of Cancer Research UK said, “However, it’s too early to say whether this research will be safe or effective in humans as they’ve only studied it in mice and cells. But we look forward to seeing future results.”
In a year’s time, the trial would start and it would involve a small number of 20 to 40 patients. And the team is focusing first on pancreatic cancer.